

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*

(於中華人民共和國註冊成立的股份有限公司)

(股份代號：1513)

**FURTHER ANNOUNCEMENT ON THE PROPOSED ADOPTION OF THE
2018 SHARE OPTIONS INCENTIVE SCHEME**

Reference is made to the announcements of the Company dated 17 July 2018 (the “**First Announcement**”) and 29 July 2018 in relation to, among others, the proposed adoption of the Incentive Scheme. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the First Announcement.

Pursuant to the communication between the Company and the Stock Exchange, the terms of the Incentive Scheme are amended to the effect that there will be no adjustment on the Exercise Price of the Share Options in the event of declaration of dividend. For further details, please refer to the circular containing, among others, full text of the terms of the Incentive Scheme to be dispatched by the Company in due course.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China
17 August 2018

As at the date of this announcement, the Executive Directors of the Company are Mr. Tao Desheng (Vice Chairman and President), Mr. Fu Daotian (Vice President) and Mr. Xu Guoxiang (Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman) and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Xu Yanjun, Mr. Guo Guoqing, Mr. Wang Xiaojun, Mr. Zheng Zhihua and Mr. Xie Yun.

** For identification purpose only*